Human Beta Defensin-2 mRNA and Proteasome Subunit β Type 8 mRNA Analysis, Useful in Differentiating Skin Biopsies from Atopic Dermatitis and Psoriasis Vulgaris Patients.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

beta-Defensins*/genetics ; beta-Defensins*/metabolism ; Dermatitis, Atopic*/genetics ; Dermatitis, Atopic*/metabolism ; Dermatitis, Atopic*/pathology ; Dermatitis, Atopic*/diagnosis ; Psoriasis*/genetics ; Psoriasis*/metabolism ; Psoriasis*/pathology ; Psoriasis*/diagnosis ; RNA, Messenger*/genetics ; RNA, Messenger*/metabolism ; Skin*/metabolism ; Skin*/pathology; Adolescent ; Adult ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; Biopsy ; Diagnosis, Differential ; Proteasome Endopeptidase Complex/genetics ; Proteasome Endopeptidase Complex/metabolism

(1): Atopic dermatitis and psoriasis vulgaris are chronic, inflammatory diseases. Clinical presentation usually leads to a proper diagnosis, but sometimes neither clinical examination nor histopathological evaluation can be conclusive. Therefore, we aimed to build up a novel diagnostic tool and check it for accuracy. The main objective of our work was to differentiate between healthy skin (C), atopic dermatitis (AD) and psoriasis vulgaris (PV) biopsies on the base of involucrin (IVL) and human β-defensin-2 (hBD-2) concentrations and their mRNA, as well as mRNA for TPP2 and PSMB8. (2): ELISA for IVL and hBD-2 proteins and Real-time PCR for the relative expression of mRNA for: IVL (IVL mRNA), hBD-2 (hBD-2 mRNA), PSMB8 (PSMB8 mRNA) and TPP2 (TPP2 mRNA), isolated from skin biopsies taken from AD and PV patients and healthy volunteers were performed. (3): hBD-2 mRNA and PSMB8 mRNA correlated with some parameters of clinical assessment of inflammatory disease severity. hBD-2 mRNA expression, exclusively, was sufficient to distinguish inflammatory skin biopsies from the healthy ones. (4): hBD-2 mRNA and PSMB8 mRNA analysis were the most valuable parameters in differentiating AD and PV biopsies.

Cancers (Basel). 2023 Nov 29;15(23):. (PMID: 38067336)
Inflamm Res. 2017 Oct;66(10):833-842. (PMID: 28620798)
J Eur Acad Dermatol Venereol. 2017 Feb;31(2):205-212. (PMID: 27573025)
Immunity. 2004 Apr;20(4):495-506. (PMID: 15084277)
Skin Health Dis. 2024 Jan 16;4(2):e338. (PMID: 38577056)
Ther Adv Chronic Dis. 2021 Mar 26;12:20406223211002979. (PMID: 33854747)
Int J Mol Sci. 2023 Sep 29;24(19):. (PMID: 37834183)
Clin Dermatol. 2007 Nov-Dec;25(6):589-95. (PMID: 18021897)
Dermatology. 2024;240(2):317-328. (PMID: 37935159)
J Allergy Clin Immunol. 2011 Apr;127(4):954-64.e1-4. (PMID: 21388663)
BMJ. 2020 May 28;369:m1590. (PMID: 32467098)
J Dermatol Sci. 2018 Mar;89(3):219-225. (PMID: 29279285)
Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4412-4417. (PMID: 28396430)
Pol Merkur Lekarski. 2005 Oct;19(112):542-4. (PMID: 16379321)
Nature. 1997 Jun 26;387(6636):861. (PMID: 9202117)
Allergy. 2017 May;72(5):783-791. (PMID: 27864954)
J Eur Acad Dermatol Venereol. 2018 May;32(5):692-703. (PMID: 29114938)
Clin Immunol. 2008 Mar;126(3):332-7. (PMID: 18166499)
Clin Dermatol. 2018 Sep - Oct;36(5):595-605. (PMID: 30217272)
Immunol Allergy Clin North Am. 2017 Feb;37(1):51-61. (PMID: 27886910)
Exp Dermatol. 2018 Apr;27(4):409-417. (PMID: 28266782)
BMC Rheumatol. 2020 Aug 25;4:36. (PMID: 32864569)
Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S14-9. (PMID: 26472560)
Lancet. 2015 Sep 5;386(9997):983-94. (PMID: 26025581)
Biochim Biophys Acta. 2012 Jan;1824(1):237-45. (PMID: 21771670)
Cells. 2021 Nov 18;10(11):. (PMID: 34831438)
J Invest Dermatol. 2013 Feb;133(2):377-85. (PMID: 23014338)
J Allergy Clin Immunol. 2021 Jan;147(1):189-198. (PMID: 32526312)
J Allergy (Cairo). 2012;2012:718725. (PMID: 23193414)
Nat Immunol. 2003 Apr;4(4):375-9. (PMID: 12598896)
Int J Mol Sci. 2019 Mar 06;20(5):. (PMID: 30845706)
Nat Immunol. 2004 Jul;5(7):661-9. (PMID: 15224091)
J Invest Dermatol. 2005 Dec;125(6):1163-73. (PMID: 16354186)
J Allergy Clin Immunol. 2009 Dec;124(6):1235-1244.e58. (PMID: 20004782)
J Invest Dermatol. 2013 Feb;133(2):287-9. (PMID: 23318785)
Clin Exp Allergy. 2016 Dec;46(12):1522-1530. (PMID: 27790779)
J Invest Dermatol. 2017 Jan;137(1):18-25. (PMID: 27771048)
Clin Exp Immunol. 2017 Nov;190(2):155-166. (PMID: 28708318)
Clin Genet. 2021 Jun;99(6):780-788. (PMID: 33586135)
J Investig Allergol Clin Immunol. 2017;27(2):78-88. (PMID: 28071589)
Cell Biochem Biophys. 2013 Jul;66(3):523-8. (PMID: 23283814)
Int J Mol Sci. 2021 Oct 27;22(21):. (PMID: 34769030)
Lancet. 2016 Mar 12;387(10023):1109-1122. (PMID: 26377142)
J Am Acad Dermatol. 2017 Jan;76(1):98-105. (PMID: 27742169)
J Dtsch Dermatol Ges. 2023 Jun;21(6):648-650. (PMID: 37125494)
Br J Dermatol. 2008 Mar;158(3):437-41. (PMID: 18047519)
Cells. 2023 Jul 13;12(14):. (PMID: 37508510)
N Engl J Med. 2002 Oct 10;347(15):1151-60. (PMID: 12374875)
Am J Manag Care. 2016 Jun;22(8 Suppl):s225-37. (PMID: 27356194)
Medicine (Baltimore). 2023 Feb 10;102(6):e32844. (PMID: 36820537)
Br J Dermatol. 2007 Sep;157(3):441-9. (PMID: 17573887)
J Am Acad Dermatol. 2014 Feb;70(2):338-51. (PMID: 24290431)
Br J Dermatol. 2013 Sep;169(3):587-93. (PMID: 23647067)
J Dtsch Dermatol Ges. 2015 Nov;13(11):1119-23. (PMID: 26513068)
Int J Dermatol. 2024 Mar 3;:. (PMID: 38433076)
Leuk Res. 2004 Jan;28(1):53-61. (PMID: 14630081)
Biochimie. 2019 Nov;166:27-37. (PMID: 31108122)
Br J Dermatol. 2011 Aug;165(2):311-20. (PMID: 21740404)
Allergy. 2024 Jan;79(1):164-173. (PMID: 37864390)
Int J Mol Sci. 2020 Feb 11;21(4):. (PMID: 32054030)
J Allergy Clin Immunol. 2017 Apr;139(4S):S58-S64. (PMID: 28390478)
J Am Acad Dermatol. 2003 Dec;49(6):1088-95. (PMID: 14639390)

180 Military Institute of Medicine-National Research Institute

Keywords: atopic dermatitis (AD); human beta defensin-2 (hBD-2); involucrin (IVL); proteasome subunit beta type 8 (PSMB8); psoriasis vulgaris (PV); tripeptidyl peptidase 2 (TPP2)

0 (beta-Defensins)
0 (DEFB4A protein, human)
EC 3.4.25.1 (Proteasome Endopeptidase Complex)
0 (RNA, Messenger)
EC 3.4.25.1 (LMP7 protein)

Date Created: 20240914 Date Completed: 20240914 Latest Revision: 20241107

20241107

PMC11395582

10.3390/ijms25179192

39273140